ClinicalTrials.gg
Active, not recruitingNCT06512337ADMIREUpdated Apr 15, 2026

A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

An observational study in Plaque Psoriasis, sponsored by Bristol-Myers Squibb. Active, not recruiting at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Bristol-Myers Squibb · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
153
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Psoriasis by Bristol-Myers Squibb — 9 open to participants now, 14 under way, 4 of them phase 3. Psoriasis · Bristol-Myers Squibb.

Enrollment
13th of 14
153 · median 528
Started
2025
with 6 others
Observational
14 of 42
5 open now
Primary completion
2027-03
later than 2 of 13 live
Registered
34th of 42
by date

Among the 42 studies in Psoriasis by Bristol-Myers Squibb, this one is the 13th largest by enrollment of the 14 observational ones that give a count, is one of 7 that started in 2025, is one of 14 observational ones, reaches primary completion later than 2 of the 13 other live ones, and was the 34th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

9 of the 42 studies in Psoriasis by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Psoriasis by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Plaque psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult participants aged ≥ 18 years who have been diagnosed with moderate plaque psoriasis who are starting deucravacitinib treatment in China

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant aged 18 years or older
  • Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with Body Surface Area ≥ 3% and \< 10%
  • Participant newly initiated deucravacitinib according to the label
  • Provided written to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Participating in or planning to participate in an interventional clinical trial
  • Concomitant use of other systemic treatments for psoriasis at baseline
  • Prior treatment of deucravacitinib
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
153 participants (actual)
Patient registry
No

Groups and cohorts

  • Participants treated with deucravacitinib

    Adults with moderate plaque psoriasis who are newly initiating deucravacitinib according to the product label

    Drug: Deucravacitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants achieving Static Physician's Global Assessment (sPGA) 0/1 score

    Time frame: Week 16

  2. Participant psoriasis Body Surface Area (BSA) involvement

    Time frame: Week 16

  3. Number of participants achieving absolute Psoriasis Area and Severity Index (PASI) score ≤ 3

    Time frame: Week 16

Secondary outcomes

  1. Number of participants achieving Psoriasis Area and Severity Index (PASI) 75 response and PASI 90 response

    Time frame: Baseline and Weeks 4, 12, 24, 36, and 52

  2. Number of participants achieving absolute Psoriasis Area and Severity Index (PASI) score ≤1, ≤2, ≤3, and ≤5

    Time frame: Baseline and Weeks 4, 12, 24, 36, and 52

  3. Participants change in Participant Absolute Psoriasis Area and Severity Index (PASI) score from baseline

    Time frame: Weeks 4, 12, 16, 24, 36, and 52

  4. Number of participants achieving psoriasis Body Surface Area (BSA) involvement of ≤1% and ≤3%

    Time frame: Baseline and Weeks 4, 12, 16, 24, 36, and 52

  5. Change in Body Surface Area (BSA) involvement from baseline to follow-up

    Time frame: Weeks 4, 12, 24, 36, and 52

  6. Static Physician's Global Assessment (sPGA) 0/1 response at follow-up

    Time frame: Weeks 4, 12, 24, 36, and 52

  7. Participants change in Static Physician's Global Assessment (sPGA) score from baseline

    Time frame: Baseline and Weeks 4, 12, 16, 24, 36, and 52

  8. Number of participants achieving a Dermatology Life Quality Index (DLQI) 0/1 score

    Time frame: Baseline and Weeks 4, 12, 16, 24, 36, and 52

  9. Number of participants achieving a Dermatology Life Quality Index (DLQI) ≤ 3 score

    Time frame: Baseline and Weeks 4, 12, 16, 24, 36, and 52

  10. Change in participant Dermatology Life Quality Index (DLQI) score from baseline

    Time frame: Baseline and Weeks 4, 12, 16, 24, 36, and 52

07

Study locations

5 sites
  • Local Institution - 0001
    Guangzhou, Guangdong 510091, China
  • Local Institution - 0002
    Handan, Hebei 056029, China
  • Local Institution - 0005
    Dalian, Liaoning 116021, China
  • Local Institution - 0004
    Shanghai, Shanghai Municipality 200080, China
  • Local Institution - 0003
    Beijing, 102218, China
08

References and documents

Publications

  • Zhang Z, Tan X, Wu Z, Zhou J. Real-world outcomes of deucravacitinib in Chinese plaque psoriasis patients: a 24-week prospective study. J Dermatolog Treat. 2026 Dec;37(1):2635262. doi: 10.1080/09546634.2026.2635262. Epub 2026 Mar 2. PubMed 41769731 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Mar 2027, 25 months after the start.

Of 81 industry-sponsored observational studies under Psoriasis, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 74. This study's planned 25 months is below that.

Counting every sponsor, half of 174 studies reached it within 37 months; a quarter within 23 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2024
First posted
Jul 22, 2024
StartActual
Jan 20, 2025
Primary completionEst.
Mar 11, 2027
CompletionEst.
Mar 11, 2027
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06512337
Responsible party
Sponsor
First posted
Jul 22, 2024
Start date
Jan 20, 2025
Primary completion
Mar 11, 2027 (estimated)
Completion
Mar 11, 2027 (estimated)
Last update
Apr 15, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion